Skip to main content

Targeting Aging with Metformin (TAME)

  • Reference work entry
  • First Online:
Encyclopedia of Gerontology and Population Aging


Antiaging drugs; Biguanide; Geroprotective medication


Targeting Aging with Metformin (TAME) is a double-blind randomized placebo-controlled clinical trial that tests whether the commonly used antidiabetic drug metformin is capable of delaying the onset of age-related diseases and conditions including cancer, cardiovascular disease, and Alzheimer’s disease, by intervening into their underlying aging processes.


Metformin, a drug which is a first-line treatment of diabetes, modulates critical pathways in the biology of aging, prompting a proposal that it may be used to target aging to delay or prevent disease. Metformin has been used safely for over 60 years, is available as a generic drug, and is inexpensive. The TAME trial is being led by Dr. Nir Barzilai, who is the director of the Institute for Aging Research at the Albert Einstein College of Medicine, New York (Hall 2015; Newman et al. 2016; Barzilai et al. 2016).

Preliminary data from trials and...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions


Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ilia Stambler .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Padki, M.M., Stambler, I. (2021). Targeting Aging with Metformin (TAME). In: Gu, D., Dupre, M.E. (eds) Encyclopedia of Gerontology and Population Aging. Springer, Cham.

Download citation

Publish with us

Policies and ethics